MARAbio Systems, a tech-enabled precision immunology company, has received $19 million in Series A financing led by MAK Capital One, LLC.

MAK Capital's Michael A. Kaufman and Craig Nemiroff will join MARAbio's board of directors.

The company has developed a proprietary blood test to detect, treat and prevent Maternal Autoantibody Related Autism (MARA), a biological subtype of autism identifiable by a pattern of autoantibodies in a mother. MARA has been shown to be associated with more severe forms of autism. 

The capital will help the company commercialize its diagnostic tool. 

"MARAbio has developed the first-ever blood test for a mother that detects autoimmune-related autism in her child, and our Series A funding round is a significant milestone that will accelerate our ability to bring this test to families in 2025," Michael S. Paul, MARAbio's CEO said in a statement. 

"MAK Capital's investment will also support our efforts to develop a precision immunology platform for both the diagnosis of autism as well as the initial development of potential therapeutic interventions aimed at neutralizing the antibodies that cause MARA, ultimately preventing the MARA subtype and reducing the overall prevalence of autism."

SPRY Therapeutics, an AI-powered physical therapy practice management platform, has scored $15 million in funding, bringing its total raise to $25 million. 

Flourish Ventures led the round with participation from Together Fund, Fidelity's Eight Roads and F-prime Capital. 

SPRY's SaaS platform, SPRY EMR, is a billing-centric offering that aims to automate the billing process by integrating clinical, finance and administrative functions while addressing data entry, report generation and patient engagement. 

"SPRY is transforming physical therapy with their AI-driven platform, streamlining clinic operations and improving patient outcomes. We're excited to support their mission to empower clinics and drive greater efficiency across the industry," Manav Garg, cofounder and managing partner at Together Fund, said in a statement. 

AI-enabled biotech organization Every Cure received a five-year $60 million commitment from TED's Audacious Project to partner with patient organizations and stakeholders to identify and repurpose promising treatments to ensure patient access. 

Every Cure will use its ARPA-H-funded AI platform in laboratory and clinical studies to examine drug repurposing opportunities. 

"We are thrilled to support Every Cure's visionary mission to save lives by finding new uses for generic and off-patent drugs," Anna Verghese, executive director of The Audacious Project, said in a statement. "With the funding catalyzed through The Audacious Project, Every Cure has the potential to change the lives of the 300 million people lacking access to safe and effective treatments."